| Record Information |
|---|
| Version | 1.0 |
|---|
| Creation Date | 2009-07-21 20:26:15 UTC |
|---|
| Update Date | 2016-11-09 01:08:41 UTC |
|---|
| Accession Number | CHEM002140 |
|---|
| Identification |
|---|
| Common Name | Ethchlorvynol |
|---|
| Class | Small Molecule |
|---|
| Description | Ethchlorvynol is only found in individuals that have used or taken this drug. It is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. [Wikipedia]Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. |
|---|
| Contaminant Sources | - HMDB Contaminants - Urine
- T3DB toxins
- ToxCast & Tox21 Chemicals
|
|---|
| Contaminant Type | - Drug
- Hypnotic and Sedative
- Metabolite
- Organic Compound
- Organochloride
- Synthetic Compound
|
|---|
| Chemical Structure | |
|---|
| Synonyms | | Value | Source |
|---|
| Placidyl | Kegg | | Ethchlorovynol | MeSH | | Ethchlorvinol | MeSH | | Ethchlorvynol | MeSH |
|
|---|
| Chemical Formula | C7H9ClO |
|---|
| Average Molecular Mass | 144.600 g/mol |
|---|
| Monoisotopic Mass | 144.034 g/mol |
|---|
| CAS Registry Number | 113-18-8 |
|---|
| IUPAC Name | (1E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol |
|---|
| Traditional Name | ethchlorvynol |
|---|
| SMILES | [H]\C(Cl)=C(\[H])C(O)(CC)C#C |
|---|
| InChI Identifier | InChI=1S/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5+ |
|---|
| InChI Key | ZEHYJZXQEQOSON-AATRIKPKSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | belongs to the class of organic compounds known as ynones. These are organic compounds containing the ynone functional group, an alpha,beta unsaturated ketone group with the general structure RC#C-C(=O)R' (R' not H). |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic oxygen compounds |
|---|
| Class | Organooxygen compounds |
|---|
| Sub Class | Carbonyl compounds |
|---|
| Direct Parent | Ynones |
|---|
| Alternative Parents | |
|---|
| Substituents | - Ynone
- Tertiary alcohol
- Acetylide
- Chloroalkene
- Haloalkene
- Vinyl halide
- Vinyl chloride
- Hydrocarbon derivative
- Organochloride
- Organohalogen compound
- Alcohol
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Biological Properties |
|---|
| Status | Detected and Not Quantified |
|---|
| Origin | Exogenous |
|---|
| Cellular Locations | - Cytoplasm
- Extracellular
- Membrane
|
|---|
| Biofluid Locations | Not Available |
|---|
| Tissue Locations | Not Available |
|---|
| Pathways | Not Available |
|---|
| Applications | |
|---|
| Biological Roles | Not Available |
|---|
| Chemical Roles | Not Available |
|---|
| Physical Properties |
|---|
| State | Liquid |
|---|
| Appearance | Not Available |
|---|
| Experimental Properties | | Property | Value |
|---|
| Melting Point | < 25°C | | Boiling Point | 28.5-30°C | | Solubility | 1.43e-01 g/L |
|
|---|
| Predicted Properties | |
|---|
| Spectra |
|---|
| Spectra | | Spectrum Type | Description | Splash Key | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0002-3900000000-198eb76a2aa919525f42 | Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0002-3900000000-e1616a7a6e75f2940d8c | Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0159-9000000000-b25f488adecb3fd0ff42 | Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0006-4900000000-2980fab2cceb6fc96107 | Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0006-3900000000-a6b1e1a57494f22868dd | Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0a59-9400000000-b1fe9dd4623953d5d8ba | Spectrum |
|
|---|
| Toxicity Profile |
|---|
| Route of Exposure | Oral, rapidly absorbed from gastrointestinal tract. |
|---|
| Mechanism of Toxicity | Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. |
|---|
| Metabolism | About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation.
Half Life: Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours. |
|---|
| Toxicity Values | Not Available |
|---|
| Lethal Dose | Not Available |
|---|
| Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
|---|
| Uses/Sources | Used for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents. |
|---|
| Minimum Risk Level | Not Available |
|---|
| Health Effects | They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive. |
|---|
| Symptoms | Symptoms of overdose include thrombocytopenia. |
|---|
| Treatment | Not Available |
|---|
| Concentrations |
|---|
| Not Available |
|---|
| External Links |
|---|
| DrugBank ID | Not Available |
|---|
| HMDB ID | Not Available |
|---|
| FooDB ID | Not Available |
|---|
| Phenol Explorer ID | Not Available |
|---|
| KNApSAcK ID | Not Available |
|---|
| BiGG ID | Not Available |
|---|
| BioCyc ID | Not Available |
|---|
| METLIN ID | Not Available |
|---|
| PDB ID | Not Available |
|---|
| Wikipedia Link | Not Available |
|---|
| Chemspider ID | Not Available |
|---|
| ChEBI ID | Not Available |
|---|
| PubChem Compound ID | 5281077 |
|---|
| Kegg Compound ID | C07833 |
|---|
| YMDB ID | Not Available |
|---|
| ECMDB ID | Not Available |
|---|
| References |
|---|
| Synthesis Reference | Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas.
Pfizer & Co., Inc. |
|---|
| MSDS | Not Available |
|---|
| General References | Not Available |
|---|